Immunic Inc (IMUX)

Currency in USD
9.650
+0.030(+0.31%)
Closed·
9.617-0.033(-0.34%)
·
Earnings results expected in 5 days
IMUX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.2509.810
52 wk Range
0.58415.100
Key Statistics
Prev. Close
9.62
Open
9.57
Day's Range
9.25-9.81
52 wk Range
0.584-15.1
Volume
185.09K
Average Volume (3m)
400.85K
1-Year Change
-7.7871%
Book Value / Share
-0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMUX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.571
Upside
+455.14%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Immunic Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 53.571
(+455.14% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy22.00+127.98%5.00MaintainApr 30, 2026
Stifel
Buy2.50-74.09%-New CoverageApr 16, 2026
D. Boral Capital
Hold---DowngradeApr 15, 2026
Guggenheim
Buy7.00-27.46%-New CoverageMar 24, 2026
H.C. Wainwright
Buy5.00-48.19%8.00MaintainMar 02, 2026

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.62 / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMUX Income Statement

Compare IMUX to Peers and Sector

Metrics to compare
IMUX
Peers
Sector
Relationship
P/E Ratio
−1.4x−2.1x−0.5x
PEG Ratio
−0.04−0.050.00
Price/Book
−19.7x4.1x2.6x
Price / LTM Sales
-9.3x3.2x
Upside (Analyst Target)
-67.1%47.8%
Fair Value Upside
Unlock3.5%6.7%Unlock

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
16.26M12.46%156.88M
Other Institutional Investors
89.92M68.92%867.74M
Public Companies & Retail Investors
24.29M18.62%234.37M
Total
130.46M100.00%1.26B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Avidity Partners Management, L.P.10.70%13,958,410134,699
Avidity Private Master Fund I LP10.70%13,958,410134,699

People Also Watch

1.330
QNCX
+1.53%
2.150
ALLO
+0.94%
0.436
IMMP
-5.62%
0.109
KALA
+3.81%
3.74
BATL
-1.32%

FAQ

What Is the Immunic (IMUX) Stock Price Today?

The Immunic stock price today is 9.650 USD.

What Stock Exchange Does Immunic Trade On?

Immunic is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunic?

The stock symbol for Immunic is "IMUX."

What Is the Immunic Market Cap?

As of today, Immunic market cap is 131.240M USD.

What Is Immunic's Earnings Per Share (TTM)?

The Immunic EPS (TTM) is -6.242.

When Is the Next Immunic Earnings Date?

Immunic will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is IMUX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immunic Stock Split?

Immunic has split 2 times.

How Many Employees Does Immunic Have?

Immunic has 92 employees.

What is the current trading status of Immunic (IMUX)?

As of May 02, 2026, Immunic (IMUX) is trading at a price of 9.650 USD, with a previous close of 9.620 USD. The stock has fluctuated within a day range of 9.250 USD to 9.810 USD, while its 52-week range spans from 0.584 USD to 15.100 USD.

What Is Immunic (IMUX) Price Target According to Analysts?

The average 12-month price target for Immunic is 53.571 USD, with a high estimate of 100 USD and a low estimate of 25 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +455.14% Upside potential.

What Is the IMUX Premarket Price?

IMUX's last pre-market stock price is 9.980 USD. The pre-market share volume is 320.000, and the stock has decreased by 0.360, or 3.740%.

What Is the IMUX After Hours Price?

IMUX's last after hours stock price is 9.617 USD, the stock has decreased by -0.033, or -0.340%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.